[PSA testing, biopsy and cancer and benign prostate hyperplasia in France].

Autor:	Tuppin P; Caisse nationale d'assurance maladie des travailleurs salariés (CNAMTS), direction de la stratégie des études et des statistiques, 26-50, avenue du Professeur-André-Lemierre, 75986 Paris cedex 20, France. Electronic address: philippe.tuppin@cnamts.fr., Samson S; Caisse nationale d'assurance maladie des travailleurs salariés (CNAMTS), direction de la stratégie des études et des statistiques, 26-50, avenue du Professeur-André-Lemierre, 75986 Paris cedex 20, France., Fagot-Campagna A; Caisse nationale d'assurance maladie des travailleurs salariés (CNAMTS), direction de la stratégie des études et des statistiques, 26-50, avenue du Professeur-André-Lemierre, 75986 Paris cedex 20, France., Lukacs B; Service d'urologie, hôpital Tenon, Assistance publique-Hôpitaux de Paris, 75020 Paris, France., Alla F; Caisse nationale d'assurance maladie des travailleurs salariés (CNAMTS), direction de la stratégie des études et des statistiques, 26-50, avenue du Professeur-André-Lemierre, 75986 Paris cedex 20, France., Allemand H; Caisse nationale d'assurance maladie des travailleurs salariés (CNAMTS), direction de la stratégie des études et des statistiques, 26-50, avenue du Professeur-André-Lemierre, 75986 Paris cedex 20, France., Paccaud F; Membres du groupe de travail du conseil scientifique de la CNAMTS, 75986 Paris cedex 20, France., Thalabard JC; Membres du groupe de travail du conseil scientifique de la CNAMTS, 75986 Paris cedex 20, France., Vicaut E; Membres du groupe de travail du conseil scientifique de la CNAMTS, 75986 Paris cedex 20, France., Vidaud M; Membres du groupe de travail du conseil scientifique de la CNAMTS, 75986 Paris cedex 20, France., Millat B; Membres du groupe de travail du conseil scientifique de la CNAMTS, 75986 Paris cedex 20, France.
Jazyk:	francouzština
Zdroj:	Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie [Prog Urol] 2014 Jul; Vol. 24 (9), pp. 572-80. Date of Electronic Publication: 2014 Apr 16.
DOI:	10.1016/j.purol.2014.03.004
Abstrakt:	Introduction: Prostate-specific antigen (PSA) testing is high in France. The aim of this study was to estimate their frequency and those of biopsy and newly diagnosed cancer (PCa) according to the presence or absence of treated benign prostatic hyperplasia (BPH). Patients and Methods: This study concerned men 40 years and older covered by the main French national health insurance scheme (73 % of all men of this age). Data were collected from the national health insurance information system (SNIIRAM). This database comprehensively records all of the outpatient prescriptions and healthcare services reimbursed. This information are linked to data collected during hospitalisations. Results: The frequency of men without diagnosed PCa (10.9 millions) with at least one PSA test was very high in 2011 (men aged 40 years and older: 30 %, 70-74 years: 56 %, 85 years and older: 33 % and without HBP: 25 %, 41 % and 19 %). Men with treated BPH totalized 9 % of the study population, but 18 % of the men with at least one PSA test, 44 % of those with at least one prostate biopsy and 40 % of those with newly managed PCa. Over a 3-year period, excluding men with PCa, 88 % of men with BPH had at least one PSA test and 52 % had three or more PSA tests versus 52 % and 15 % for men without BPH. One year after PSA testing, men of 55-69 years with BPH more frequently underwent prostate biopsy than those without BPH (5.4 % vs 1.8 %) and presented PCa (1.9 % vs 0.9 %). Conclusions: PSA testing frequencies in France are very high even after exclusion of men with BPH, who can be a group with more frequent managed PCa. Level of Evidence: 4. (Copyright © 2014 Elsevier Masson SAS. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu